LIP expression is regulated by IGF-1R signaling and participates in suppression of anoikis

[1]  J. Massagué,et al.  HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPß isoforms. , 2010, Cancer research.

[2]  Hanna Y. Irie,et al.  Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment , 2009, Nature.

[3]  C. Zahnow,et al.  CCAAT/enhancer-binding protein β: its role in breast cancer and associations with receptor tyrosine kinases , 2009, Expert Reviews in Molecular Medicine.

[4]  H. Wiley,et al.  Multiple Mechanisms Are Responsible for Transactivation of the Epidermal Growth Factor Receptor in Mammary Epithelial Cells* , 2008, Journal of Biological Chemistry.

[5]  A. Welm,et al.  Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer. , 2008, Cell stem cell.

[6]  D. Reisman,et al.  C/EBPβ Participates in Regulating Transcription of the p53 Gene in Response to Mitogen Stimulation* , 2007, Journal of Biological Chemistry.

[7]  L. Chodosh,et al.  Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation , 2007, Oncogene.

[8]  R. Smart,et al.  Decreased survival of C/EBPβ-deficient keratinocytes is due to aberrant regulation of p53 levels and function , 2007, Oncogene.

[9]  C. Zahnow.  ErbB receptors and their ligands in the breast , 2006, Expert Reviews in Molecular Medicine.

[10]  Roger R. Gomis,et al.  C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells , 2006 .

[11]  Peter F. Johnson,et al.  Stop and Go: Anti-Proliferative and Mitogenic Functions of the Transcription Factor C/EBPβ , 2006, Cell cycle.

[12]  Adrian V. Lee,et al.  Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. , 2005, Cancer research.

[13]  T. Yoneda,et al.  A CCAAT/Enhancer Binding Protein β Isoform, Liver-Enriched Inhibitory Protein, Regulates Commitment of Osteoblasts and Adipocytes , 2005, Molecular and Cellular Biology.

[14]  H. Werner,et al.  Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling , 2005, Oncogene.

[15]  Siegal Sadetzki,et al.  Diabetes mellitus and breast cancer. , 2005, The Lancet. Oncology.

[16]  R. Nicholson,et al.  Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. , 2004, Endocrine-related cancer.

[17]  E. Gehan,et al.  The Nuclear Receptor Coactivator AIB1 Mediates Insulin-like Growth Factor I-induced Phenotypic Changes in Human Breast Cancer Cells , 2004, Cancer Research.

[18]  L. Luttrell,et al.  Ectodomain shedding-dependent transactivation of epidermal growth factor receptors in response to insulin-like growth factor type I. , 2004, Molecular endocrinology.

[19]  T. Luedde,et al.  C/EBP β isoforms LIP and LAP modulate progression of the cell cycle in the regenerating mouse liver , 2004, Hepatology.

[20]  Nikolai A. Timchenko,et al.  Epidermal Growth Factor Receptor Stimulation Activates the RNA Binding Protein CUG-BP1 and Increases Expression of C/EBPβ-LIP in Mammary Epithelial Cells , 2004, Molecular and Cellular Biology.

[21]  R. C. Schwartz,et al.  CCAAT/enhancer-binding protein-β has a role in osteoblast proliferation and differentiation , 2004 .

[22]  Peter F. Johnson,et al.  Critical Prosurvival Roles for C/EBPβ and Insulin-Like Growth Factor I in Macrophage Tumor Cells , 2004, Molecular and Cellular Biology.

[23]  N. Anderson,et al.  The Mitogenic Action of Insulin-like Growth Factor I in Normal Human Mammary Epithelial Cells Requires the Epidermal Growth Factor Receptor Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[24]  F. Peruzzi,et al.  The IGF‐1 receptor in cancer biology , 2003, International journal of cancer.

[25]  J. Chappell,et al.  Enhanced insulin signaling via Shc in human breast cancer. , 2003, Metabolism: clinical and experimental.

[26]  T. Golub,et al.  A Mechanism of Cyclin D1 Action Encoded in the Patterns of Gene Expression in Human Cancer , 2003, Cell.

[27]  Dennis C. Sgroi,et al.  Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis , 2003, Nature Cell Biology.

[28]  K. Milde-Langosch,et al.  Expression of the CCAAT/Enhancer-Binding Proteins C/EBPα, C/EBPβ and C/EBPδ in Breast Cancer: Correlations with Clinicopathologic Parameters and Cell-Cycle Regulatory Proteins , 2003, Breast Cancer Research and Treatment.

[29]  E. Surmacz,et al.  Role of the IGF‐I receptor in the regulation of cell–cell adhesion: Implications in cancer development and progression , 2003, Journal of cellular physiology.

[30]  P. Dennis,et al.  Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. , 2003, Journal of the American Chemical Society.

[31]  A. Belfiore,et al.  Insulin/Insulin-like Growth Factor I Hybrid Receptors Have Different Biological Characteristics Depending on the Insulin Receptor Isoform Involved* , 2002, The Journal of Biological Chemistry.

[32]  S. Korsmeyer,et al.  Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor* , 2002, The Journal of Biological Chemistry.

[33]  T. Wood,et al.  Requirement for IGF-I in epidermal growth factor-mediated cell cycle progression of mammary epithelial cells. , 2002, Endocrinology.

[34]  C. Zahnow.  CCAAT/enhancer binding proteins in normal mammary development and breast cancer , 2002, Breast Cancer Research.

[35]  R. Smart,et al.  CCAAT/enhancer binding protein-β is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Hadsell,et al.  Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. , 2001, Endocrinology.

[37]  T. Hunter,et al.  C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival. , 2001, Molecular cell.

[38]  W. Xiong,et al.  Regulation of CCAAT/enhancer-binding protein-beta isoform synthesis by alternative translational initiation at multiple AUG start sites. , 2001, Nucleic acids research.

[39]  C. Benz,et al.  A role for both Ets and C/EBP transcription factors and mRNA stabilization in the MAPK-dependent increase in p21 (Cip-1/WAF1/mda6) protein levels in primary hepatocytes. , 2000, Molecular biology of the cell.

[40]  A. Leutz,et al.  Translational control of C/EBPalpha and C/EBPbeta isoform expression. , 2000, Genes & development.

[41]  K. L. Pierce,et al.  Transactivation of the EGF Receptor Mediates IGF-1-stimulated Shc Phosphorylation and ERK1/2 Activation in COS-7 Cells* , 2000, The Journal of Biological Chemistry.

[42]  Qiang Tian,et al.  The C/EBP bZIP Domain Can Mediate Lipopolysaccharide Induction of the Proinflammatory Cytokines Interleukin-6 and Monocyte Chemoattractant Protein-1* , 2000, The Journal of Biological Chemistry.

[43]  K. Siddle,et al.  Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  S. Soddu,et al.  Growth and Differentiation Signals by the Insulin-like Growth Factor 1 Receptor in Hemopoietic Cells Are Mediated through Different Pathways* , 1999, The Journal of Biological Chemistry.

[45]  Sandra,et al.  A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. , 1998, Cancer research.

[46]  L. Hennighausen,et al.  The C/EBPbeta transcription factor regulates epithelial cell proliferation and differentiation in the mammary gland. , 1998, Genes & development.

[47]  Brian Raught,et al.  C/EBPβ, but not C/EBPα, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland , 1998 .

[48]  C. Zahnow,et al.  Overexpression of C/EBPβ-LIP, a Naturally Occurring, Dominant-Negative Transcription Factor, in Human Breast Cancer , 1997 .

[49]  C. Hsieh,et al.  Evidence for posttranscriptional regulation of C/EBPalpha and C/EBPbeta isoform expression during the lipopolysaccharide-mediated acute-phase response , 1996, Molecular and cellular biology.

[50]  R. Cardiff,et al.  Activated neu Induces Rapid Tumor Progression (*) , 1996, The Journal of Biological Chemistry.

[51]  D. Riley,et al.  Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Baserga,et al.  Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. , 1995, Cancer research.

[53]  F. M. V. Van Schaik,et al.  Expression of the insulin-like growth factor I gene is stimulated by the liver-enriched transcription factors C/EBP alpha and LAP. , 1994, Molecular endocrinology.

[54]  S. Frisch,et al.  Disruption of epithelial cell-matrix interactions induces apoptosis , 1994, The Journal of cell biology.

[55]  K. Siddle,et al.  Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. , 1993, The Biochemical journal.

[56]  U. Schibler,et al.  A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the sam mRNA , 1991, Cell.

[57]  R. Palmiter,et al.  Overexpression of TGFα in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast , 1990, Cell.

[58]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[59]  J. Massagué,et al.  C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. , 2006, Cancer cell.

[60]  C. Zahnow,et al.  Epidermal growth factor receptor stimulation activates the RNA binding protein CUG-BP1 and increases expression of C/EBPbeta-LIP in mammary epithelial cells. , 2004, Molecular and cellular biology.

[61]  E. Surmacz.  Function of the IGF-I Receptor in Breast Cancer , 2004, Journal of Mammary Gland Biology and Neoplasia.

[62]  R. C. Schwartz,et al.  CCAAT/enhancer-binding protein-beta has a role in osteoblast proliferation and differentiation. , 2004, Experimental cell research.

[63]  F. Frasca,et al.  Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. , 2003, Breast disease.

[64]  T. Löning,et al.  Expression of the CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins. , 2003, Breast cancer research and treatment.

[65]  J. Brosens,et al.  Functional association of PR and CCAAT/enhancer-binding protein beta isoforms: promoter-dependent cooperation between PR-B and liver-enriched inhibitory protein, or liver-enriched activatory protein and PR-A in human endometrial stromal cells. , 2002, Molecular endocrinology.

[66]  C. Zahnow,et al.  A role for CCAAT/enhancer binding protein beta-liver-enriched inhibitory protein in mammary epithelial cell proliferation. , 2001, Cancer research.

[67]  W. Ruan,et al.  Insulin-Like Growth Factor I Is Essential for Terminal End Bud Formation and Ductal Morphogenesis during Mammary Development1. , 1999, Endocrinology.

[68]  B. Raught,et al.  C/EBPbeta, but not C/EBPalpha, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland. , 1998, Genes & development.

[69]  C. Zahnow,et al.  Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. , 1997, Journal of the National Cancer Institute.